IND Enabling
Phase I
Phase II
Phase III
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Anhui Kedgene Biotechnology
Main focus: Next generation T cell-based therapies
Company stage: Clinical
Diseases: Solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Anhui, China
Anhui Kedgene Biotechnology develops next generation T cell-based therapies for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimise efficacy and safety.
